Re: Farmas USA
CELG
cash and stock consideration to be received by Celgene shareholders at closing is valued at $102.43 per Celgene share and one CVR (as described below). When completed, Bristol-Myers Squibb shareholders are expected to own approximately 69 percent of the company, and Celgene shareholders are expected to own approximately 31 percent.
Yo no he pensado mucho. He visto que no aguantaba los 90 y he vendido sin más.
«Después de nada, o después de todo/ supe que todo no era más que nada.»